ST (600079.SH) subsidiary's application for clinical trial of Sufentanil Citrate Injection has been approved.

Zhitong Finance APP reported that ST Renfu (600079.SH) announced that its controlling subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (hereinafter referred to as "Yichang Renfu") has recently received the "Approval Notice for Clinical Trials" for Citric Acid Sufofentanil Injection issued by the National Medical Products Administration.